Second, many studies have assessed clinicopathological factors based on 3-years survival, whereas we demonstrated that KIF4A exerted an additive effect over a longer period with the 8-years survival of patients with HCC. This evidence concerns the gene KIF4A and hepatocellular carcinoma.